Mixed trend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 23 · inside the Ichimoku cloud · RSI 0 (oversold) · MACD above its signal · at its 52-week high
None of the 29 investors followed here reported a position in CMRA in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CMRA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for CMRA.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | ||
| 2025 | 0.0 | 0.0 | 0.0 | -50.0 | 100.0 | 0.0 | 0.0 | 0.0 | -50.0 | 0.0 | 0.0 | 0.0 | −50.0% |
| 2024 | -32.7 | 9.5 | -16.0 | 17.6 | -43.2 | 10.1 | -11.2 | 0.0 | 0.0 | -99.5 | 100.0 | 0.0 | −99.6% |
| 2023 | 10.6 | -9.6 | -26.9 | -18.6 | -30.3 | -4.4 | 22.1 | -26.7 | -33.2 | 1.2 | -72.9 | -31.2 | −95.5% |
| 2022 | 20.5 | 48.9 | -55.0 | -9.0 | -7.5 | 2.7 | -19.6 | −43.8% |
No analyst coverage for this instrument.
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
No recent headlines.